Preventing blood clots in patients undergoing varicose vein treatment
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial
This study tests different blood-thinning medications to see which one best helps prevent blood clots in adults getting treatment for varicose veins.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 6660 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Imperial College London Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT05735639 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of various anticoagulants in preventing venous thromboembolism (VTE) in adults undergoing endovenous interventions for truncal varicose veins. The research focuses on patients scheduled for minimally invasive procedures such as radiofrequency, laser, and sclerotherapy, which may increase the risk of blood clots. By comparing different anticoagulant treatments, the study aims to determine the best approach to reduce the incidence of VTE following these procedures.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 scheduled for endovenous interventions for truncal varicose veins under local anesthesia.
Not a fit: Patients with a history of venous thromboembolism, certain bleeding disorders, or those requiring therapeutic anticoagulation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the risk of blood clots in patients undergoing varicose vein treatments, improving patient safety and outcomes.
How similar studies have performed: Other studies have shown varying success with anticoagulant use in similar surgical contexts, but this specific approach is still being evaluated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (\>18 years) * Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia * Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue Exclusion Criteria: * Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation * Previous personal or first-degree relative history of VTE * Thrombophilia * Female patients of childbearing potential who have a positive pregnancy test * A history of allergy to heparins or direct oral anticoagulants * A history of heparin-induced thrombocytopenia * Inherited and acquired bleeding disorders * Evidence of active bleeding * Concomitant major health problems such as active cancer and chronic renal and/or liver impairment * Known thrombocytopenia (platelets known to be less than 50 x 109 /l) * Surgery or major trauma in the previous 90 days * Recent ischemic stroke in the previous 90 days * Inability to provide consent
Where this trial is running
London
- Imperial College Hospital NHS Foundation Trust — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Sarah Whittley
- Email: s.whittley@imperial.ac.uk
- Phone: +442033117309
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.